DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment-Reference-Cited by-同舟云学术

DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment

Published:2021-02-13 Issue:4 Volume:37 Page:589-596
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Pavelek Zbyšek¹,Novotný Michal¹,Klímová Blanka¹,Peterka Marek²,Potužník Pavel²,Kövári Martina³,Vališ Martin¹

Affiliation:

1. Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

2. Department of Neurology, University Hospital Plzen, Plzen, Czech Republic

3. Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1880886

Reference33 articles.

1. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

2. Factors involved in relapse of multiple sclerosis

3. The direct costs of multiple sclerosis—study in the Czech Republic

4. A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

5. PRISMS-4: Long-term efficacy of interferon- -1a in relapsing MS

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

2. Evolution of the RebiSmart® Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis;Patient Preference and Adherence;2023-08

3. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis;European Neurology;2023-07-20

4. Interferon-β-1a;Reactions Weekly;2021-07